These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31492896)

  • 21. Differential niche and Wnt requirements during acute myeloid leukemia progression.
    Lane SW; Wang YJ; Lo Celso C; Ragu C; Bullinger L; Sykes SM; Ferraro F; Shterental S; Lin CP; Gilliland DG; Scadden DT; Armstrong SA; Williams DA
    Blood; 2011 Sep; 118(10):2849-56. PubMed ID: 21765021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LIGHT/LTβR signaling regulates self-renewal and differentiation of hematopoietic and leukemia stem cells.
    Höpner SS; Raykova A; Radpour R; Amrein MA; Koller D; Baerlocher GM; Riether C; Ochsenbein AF
    Nat Commun; 2021 Feb; 12(1):1065. PubMed ID: 33594067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia.
    Liu Y; Wang G; Zhang J; Chen X; Xu H; Heng G; Chen J; Zhao Y; Li J; Ni Y; Zhang Y; Shan J; Qian C
    Stem Cell Res Ther; 2021 Jan; 12(1):86. PubMed ID: 33494824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.
    Iwasaki M; Liedtke M; Gentles AJ; Cleary ML
    Cell Stem Cell; 2015 Oct; 17(4):412-21. PubMed ID: 26387756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes.
    Yanagisawa B; Perkins B; Karantanos T; Levis M; Ghiaur G; Smith BD; Jones RJ
    Leuk Res; 2020 Dec; 99():106477. PubMed ID: 33220589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PI3Kγ maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway.
    Gu H; Chen C; Hou ZS; He XD; Xie S; Ni J; Qian C; Cheng X; Jiang T; Yang C; Roberts TM; Zheng J; Varner JA; Armstrong SA; Zhao JJ
    Blood; 2024 May; 143(19):1965-1979. PubMed ID: 38271660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML.
    Wang Y; Krivtsov AV; Sinha AU; North TE; Goessling W; Feng Z; Zon LI; Armstrong SA
    Science; 2010 Mar; 327(5973):1650-3. PubMed ID: 20339075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GPR84 sustains aberrant β-catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesis.
    Dietrich PA; Yang C; Leung HH; Lynch JR; Gonzales E; Liu B; Haber M; Norris MD; Wang J; Wang JY
    Blood; 2014 Nov; 124(22):3284-94. PubMed ID: 25293777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myc-Miz1 signaling promotes self-renewal of leukemia stem cells by repressing Cebpα and Cebpδ.
    Zhang L; Li J; Xu H; Shao X; Fu L; Hou Y; Hao C; Li W; Joshi K; Wei W; Xu Y; Zhang F; Dai S; Breslin P; Zhang J; Zhang J
    Blood; 2020 Apr; 135(14):1133-1145. PubMed ID: 32040550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia.
    Kikushige Y; Miyamoto T
    Oncology; 2015; 89 Suppl 1():28-32. PubMed ID: 26551150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute myeloid leukemia: therapeutic targeting of stem cells.
    Pabon CM; Abbas HA; Konopleva M
    Expert Opin Ther Targets; 2022 Jun; 26(6):547-556. PubMed ID: 35634856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RSPO2 inhibits BMP signaling to promote self-renewal in acute myeloid leukemia.
    Sun R; He L; Lee H; Glinka A; Andresen C; Hübschmann D; Jeremias I; Müller-Decker K; Pabst C; Niehrs C
    Cell Rep; 2021 Aug; 36(7):109559. PubMed ID: 34407399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting acute myeloid leukemia stem cell signaling by natural products.
    Siveen KS; Uddin S; Mohammad RM
    Mol Cancer; 2017 Jan; 16(1):13. PubMed ID: 28137265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of cantharidins on leukemic stem cells.
    Dorn DC; Kou CA; Png KJ; Moore MA
    Int J Cancer; 2009 May; 124(9):2186-99. PubMed ID: 19123473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells.
    Pelosi E; Castelli G; Testa U
    Blood Cells Mol Dis; 2015 Dec; 55(4):336-46. PubMed ID: 26460257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.
    Kikushige Y; Miyamoto T
    Int J Hematol; 2013 Dec; 98(6):627-33. PubMed ID: 24046178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alternative splicing of HOXB-AS3 underlie the promoting effect of nuclear m6A reader YTHDC1 on the self-renewal of leukemic stem cells in acute myeloid leukemia.
    Wu C; Cui J; Huo Y; Shi L; Wang C
    Int J Biol Macromol; 2023 May; 237():123990. PubMed ID: 36906205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors.
    Venton G; Pérez-Alea M; Baier C; Fournet G; Quash G; Labiad Y; Martin G; Sanderson F; Poullin P; Suchon P; Farnault L; Nguyen C; Brunet C; Ceylan I; Costello RT
    Blood Cancer J; 2016 Sep; 6(9):e469. PubMed ID: 27611922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of mTORC1-S6K1 signaling pathway in regulation of hematopoietic stem cell and acute myeloid leukemia.
    Ghosh J; Kapur R
    Exp Hematol; 2017 Jun; 50():13-21. PubMed ID: 28342808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia.
    Kikushige Y; Akashi K
    Ann N Y Acad Sci; 2012 Aug; 1266():118-23. PubMed ID: 22901263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.